Total Payments
$476,431
2024 Payments
$75,533
Companies
22
Transactions
437
Medicare Patients
2,808
Medicare Billing
$326,176
Payment Breakdown by Category
Other$378,436 (79.4%)
Consulting$45,759 (9.6%)
Travel$44,096 (9.3%)
Food & Beverage$8,037 (1.7%)
Education$103.15 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $378,436 | 121 | 79.4% |
| Consulting Fee | $45,759 | 32 | 9.6% |
| Travel and Lodging | $44,096 | 154 | 9.3% |
| Food and Beverage | $8,037 | 126 | 1.7% |
| Education | $103.15 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $164,829 | 144 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $139,236 | 109 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $101,669 | 97 | $0 (2024) |
| GENZYME CORPORATION | $31,430 | 25 | $0 (2023) |
| Mirati Therapeutics, Inc. | $19,409 | 20 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $16,756 | 18 | $0 (2023) |
| Seattle Genetics, Inc. | $1,513 | 2 | $0 (2019) |
| F. Hoffmann-La Roche AG | $1,185 | 2 | $0 (2019) |
| Daiichi Sankyo Inc. | $128.70 | 2 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $43.59 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $75,533 | 77 | Regeneron Healthcare Solutions, Inc. ($39,619) |
| 2023 | $126,923 | 105 | E.R. Squibb & Sons, L.L.C. ($53,894) |
| 2022 | $105,226 | 106 | E.R. Squibb & Sons, L.L.C. ($45,438) |
| 2021 | $69,756 | 54 | E.R. Squibb & Sons, L.L.C. ($29,847) |
| 2020 | $36,740 | 21 | AstraZeneca Pharmaceuticals LP ($30,155) |
| 2019 | $43,087 | 39 | AstraZeneca Pharmaceuticals LP ($40,352) |
| 2018 | $18,874 | 16 | AstraZeneca Pharmaceuticals LP ($18,797) |
| 2017 | $291.08 | 19 | Merck Sharp & Dohme Corporation ($43.59) |
All Payment Transactions
437 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $860.00 | General |
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $888.53 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,854.00 | General |
| Category: Oncology | ||||||
| 11/23/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $218.50 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,272.00 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $813.72 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $238.05 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $100.56 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,272.00 | General |
| Category: ONCOLOGY | ||||||
| 11/02/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $1,125.46 | General |
| Category: ONCOLOGY | ||||||
| 11/02/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $245.26 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $78.43 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $755.95 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,704.00 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 10/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $635.95 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $111.91 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $284.73 | General |
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $184.73 | General |
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $100.00 | General |
| 08/01/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $60.02 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $34.17 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $12.33 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 501 | 930 | $128,258 | $68,084 |
| 2022 | 11 | 628 | 1,037 | $159,623 | $73,665 |
| 2021 | 12 | 780 | 1,371 | $166,770 | $94,999 |
| 2020 | 13 | 899 | 1,534 | $190,093 | $89,429 |
Total Patients
2,808
Total Services
4,872
Medicare Billing
$326,176
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 206 | 506 | $53,452 | $34,798 | 65.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 70 | 159 | $24,091 | $16,124 | 66.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 122 | 145 | $10,105 | $5,913 | 58.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $5,360 | $2,936 | 54.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 30 | 45 | $10,845 | $2,769 | 25.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 19 | $12,521 | $2,519 | 20.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 21 | $10,080 | $2,024 | 20.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $1,804 | $1,001 | 55.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 190 | 466 | $51,404 | $31,864 | 62.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 61 | 106 | $17,195 | $11,554 | 67.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 168 | 214 | $16,332 | $8,915 | 54.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 36 | $23,319 | $5,604 | 24.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 45 | 45 | $8,073 | $4,420 | 54.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 45 | 71 | $16,756 | $3,801 | 22.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 22 | 23 | $10,690 | $2,480 | 23.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 29 | $9,831 | $2,317 | 23.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $2,669 | $1,726 | 64.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 15 | 22 | $2,816 | $665.71 | 23.6% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 12 | 12 | $538.00 | $318.49 | 59.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 242 | 697 | $74,336 | $50,582 | 68.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 211 | 278 | $19,889 | $12,093 | 60.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 58 | 86 | $13,586 | $9,642 | 71.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 63 | 63 | $11,075 | $6,386 | 57.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 21 | $12,138 | $3,322 | 27.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 43 | 59 | $9,794 | $3,293 | 33.6% |
About Dr. Raghava Induru, MD
Dr. Raghava Induru, MD is a Hospice and Palliative Medicine healthcare provider based in Albemarle, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1063608388.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raghava Induru, MD has received a total of $476,431 in payments from pharmaceutical and medical device companies, with $75,533 received in 2024. These payments were reported across 437 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($378,436).
As a Medicare-enrolled provider, Induru has provided services to 2,808 Medicare beneficiaries, totaling 4,872 services with total Medicare billing of $326,176. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospice and Palliative Medicine
- Other Specialties Internal Medicine, Medical Oncology
- Location Albemarle, NC
- Active Since 09/20/2007
- Last Updated 07/15/2024
- Taxonomy Code 207QH0002X
- Entity Type Individual
- NPI Number 1063608388
Products in Payments
- OPDIVO (Biological) $150,845
- LIBTAYO (Biological) $139,285
- IMFINZI (Drug) $54,667
- TAGRISSO (Drug) $48,859
- IMFINZI (Biological) $30,445
- KRAZATI (Drug) $19,409
- ENHERTU (Biological) $5,245
- TECENTRIQ (Biological) $1,200
- ENHERTU (Drug) $76.20
- Enhertu (Drug) $52.50
- Lonsurf (Drug) $24.92
- FERAHEME (Drug) $23.13
- CALQUENCE (Drug) $18.97
- JAKAFI (Drug) $17.26
- GAZYVA (Biological) $16.07
- XTANDI (Drug) $15.52
- Aranesp (Biological) $15.26
- BENDEKA (Drug) $14.13
- GILOTRIF (Drug) $14.05
- IMBRUVICA (Drug) $13.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.